menu toggle

Insights

Perspective, tips, and resources for moving health forward

abstract-brand-colors-texture-2
All Insights Health Systems Pharmacies Physician Practices Manufacturers Animal Health
AmerisourceBergen

First 10 drugs for Medicare price negotiation announced under IRA

Corey Ford
Corey Ford, MHA
August 2023

HTA Quarterly | Fall 2023

Inverted color AmerisourceBergen icon
Xcenda
August 2023

Manufacturers

Only 17 months until the implementation of the new EU JCA—Latest developments and remaining uncertainties

Inverted color AmerisourceBergen icon
AmerisourceBergen
August 2023
implementation of the new EU JCA

Manufacturers

Multistakeholder perspectives on Joint Clinical Assessment in Europe

Inverted color AmerisourceBergen icon
AmerisourceBergen
August 2023
Group Physicians Wearing Masks

Manufacturers

What's next for biopharma under the inflation reduction act

Corey Ford
Corey Ford, MHA
July 2023
Coworkers at meeting

Manufacturers

Pre-launch checklist: What to look for in a commercialization partner

Inverted color AmerisourceBergen icon
AmerisourceBergen
June 2023
AB-Lab and Science-Female_RGB_Large_JPG

Manufacturers

Recap AMCP 2023: Our thought leadership in action

Inverted color AmerisourceBergen icon
Xcenda
March 2023
Team members at the AMCP 2023 exhibit

Manufacturers

Optimize your pre-approval information exchange strategy

Charles Dragovich
Charles Dragovich
March 2023
Abstract photography showing blue and white lines with a sense of motion

Manufacturers

How to forge stronger working relationships with payers

Dunn_Warren
Warren Dunn
AmerisourceBergen
March 2023
Close-up of two business women shaking hands

Manufacturers

HTA Quarterly | Spring 2023

Inverted color AmerisourceBergen icon
Xcenda
February 2023
HTA Quarterly Logo

Manufacturers

The essential guide to drug commercialization

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2023
abstract-brand-colors-texture

Manufacturers

Six essential steps for emerging biopharma companies launching a new therapy

Dunn_Warren
Warren Dunn
AmerisourceBergen
February 2023
emerging biopharma companies launching their first therapy

Manufacturers

Three questions biopharma companies must ask when building a cell and gene commercialization strategy

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2023
Cell and gene therapy commercialization

Manufacturers

Education: The centerpiece of biosimilar adoption

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2023
Biosimilars adoption

Manufacturers

New pan-EU HTA: How can biopharma navigate the joint clinical assessment?

Inverted color AmerisourceBergen icon
AmerisourceBergen
January 2023
New Pan-EU HTA

Manufacturers

Webinar: Evaluate alternative revolutionary reimbursement models to craft a sustainable business model for cell and gene therapies

A photo of David Senior wearing a dark gray suit, white collared shirt, and dark blue tie with a diamond pattern
David Senior
AmerisourceBergen
December 2022
Cell and Gene therapy alternative reimbursement models

Manufacturers

Three questions to ask about your market access partner

Inverted color AmerisourceBergen icon
AmerisourceBergen
November 2022
GettyImages-1175219989

Manufacturers

Acceleration of innovation in healthcare delivery

Teri' Burnell
Teri Burnell, PharmD; Myra Reinhardt
Biopharma Services
November 2022
Patient and doctor

Manufacturers

HTA Quarterly | Summer 2023

Inverted color AmerisourceBergen icon
Xcenda
November 2022
HTA Quarterly Logo

Manufacturers

HTA Quarterly | Winter 2022

Inverted color AmerisourceBergen icon
Xcenda
October 2022
HTA Quarterly Logo

Manufacturers

Podcast: Conversations around interchangeability and biosimilar entries in new therapeutic categories

Inverted color AmerisourceBergen icon
AmerisourceBergen
September 2022
Interchangeable biosimilars

Manufacturers

Closing the gaps in pre-approval information exchange to accelerate product success and patient access

AB-TB-Sq-Block
AmerisourceBergen
September 2022
AB color abstract

Manufacturers

Answering the challenges of rare disease market access with HEOR

AB-TB-Sq-Block
AmerisourceBergen
September 2022
Male and female coworker at conference table

Manufacturers

How will the Inflation Reduction Act affect the biopharma industry?

AB-TB-Sq-Block
AmerisourceBergen
August 2022
vaccines on top of US dollars

Manufacturers

Market access abroad: Three reasons why early planning is critical for HTA countries

AB-TB-Sq-Block
AmerisourceBergen
August 2022
Abstract image of Red Color Illuminated Fiber Optics Selective Focus on Blue Background.

Manufacturers

Podcast: Milestones for biosimilars in 2022 and looking ahead to 2023

Inverted color AmerisourceBergen icon
AmerisourceBergen
July 2022
Biosimilars podcast

Manufacturers

Innovative agreements: Exploring alternative payment models

Inverted color AmerisourceBergen icon
AmerisourceBergen
July 2022
innovative agreements

Manufacturers

Why FormularyDecisions® is the right choice for enterprise biopharma payer engagement 

Inverted color AmerisourceBergen icon
Xcenda
July 2022
formulary decisions enterprise man working on computer

Manufacturers

Webinar slides: Navigating Reimbursement and Access Challenges for Novel Cell and Gene Therapies

AB-TB-Sq-Block
Tasmina Hydery
June 2022
abstract lines

Orphan drugs: trapped in the lock? A review of the lock system in the Netherlands

Inverted color AmerisourceBergen icon
AmerisourceBergen
May 2022
Panama Canal Orphan Drug Lock Article Image

Manufacturers

Differentiate your product with FormularyDecisions®

Inverted color AmerisourceBergen icon
Xcenda
April 2022
Differentiate your product with FormularyDecisions

Manufacturers

Six insights driving the evolution of FormularyDecisions®

AB-TB-Sq-Block
Tasmina Hydery; Sara Linnerooth
March 2022
Coworkers at meeting

Webinar: Debunking common PIE misperceptions to enhance your PIE strategy and tactics

Inverted color AmerisourceBergen icon
Xcenda
March 2022
Debunking PIE misperceptions

Manufacturers

Essential skills for outsourced field solutions teams

Inverted color AmerisourceBergen icon
AmerisourceBergen
November 2021
female speaking to medical audience

Manufacturers

Building your field reimbursement and access team: The translational experience and skills that matter most

Inverted color AmerisourceBergen icon
AmerisourceBergen
September 2021
health insurance claim form

Manufacturers

eBook: Bringing innovation to market with digital therapeutics

Inverted color AmerisourceBergen icon
Lash Group
August 2021
woman using smartphone on yellow couch

Manufacturers

Navigating the payer landscape for digital therapeutics

Inverted color AmerisourceBergen icon
Lash Group
June 2021
woman on smartphone in urban setting

Manufacturers

Patient support for digital therapeutics: Do's and don'ts for designing your program

Inverted color AmerisourceBergen icon
Lash Group
June 2021
young man on smartphone pink wall

Manufacturers

Work worth doing: Innovative field solutions

Inverted color AmerisourceBergen icon
AmerisourceBergen
June 2021
female speaking to medical audience

Manufacturers

Innomar Strategies: 20 years of innovative market access solutions

Inverted color AmerisourceBergen icon
Innomar Strategies
June 2021

Manufacturers

Work worth doing: FormularyDecisions

AB-TB-Sq-Block
Laurie Fazio
Xcenda
May 2021
abstract-blues-tech

Manufacturers

Podcast: ThinkLive Commercialization 2021

Sarnes_Matt
Matt Sarnes, PharmD
Biopharma Services
May 2021
audience

Manufacturers

On-demand webinar: Accelerating access to therapy (a view from the front lines)

Inverted color AmerisourceBergen icon
AmerisourceBergen
April 2021
Accelerating access to therapy

Manufacturers

The hidden value of integrated commercialization services: A manufacturer’s perspective

Inverted color AmerisourceBergen icon
AmerisourceBergen
April 2021
AB new brand magenta texture

Manufacturers

Ebook: Strategic partnerships for unlocking product potential

Inverted color AmerisourceBergen icon
AmerisourceBergen
April 2021
Strategic partnerships for unlocking product potential ebook

Manufacturers

The Value of Real-World Evidence in Canadian Drug Commercialization: Part 2

Inverted color AmerisourceBergen icon
Innomar Strategies
April 2021

Manufacturers

How to make the most of integrated commercialization solutions

Glen Martin headshot
Glen Martin
AmerisourceBergen
March 2021
AmerisourceBergen manufacturer commercialization strategies

Manufacturers

Strategies for addressing copay accumulators: What manufacturers need to know

Corey Ford
Corey Ford, MHA; Dale Hanna
March 2021
copay accumulator piggy bank

Manufacturers

Webinar: uptake or heartbreak with biosimilars? Progress and perspectives

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2021
Market access professionals

Manufacturers

Checklist: Four things to look for in a field services partner

Inverted color AmerisourceBergen icon
Xcenda
February 2021
xcenda field services working on project

Manufacturers

Case study: an innovative field reimbursement program expands patient access

Inverted color AmerisourceBergen icon
Xcenda
January 2021
insurance card and tablet

Manufacturers

Cell and gene therapies: bringing innovation to market

Inverted color AmerisourceBergen icon
AmerisourceBergen
December 2020
Lab tech with DNA

Manufacturers

Pharma in the field: Ashley's story

Inverted color AmerisourceBergen icon
Xcenda
November 2020
Doctor talking to patient

Manufacturers

Pharma in the field: Tierra's story

Inverted color AmerisourceBergen icon
Xcenda
November 2020
insurance card and tablet

Manufacturers

Ebook: Virtual drug commercialization

Inverted color AmerisourceBergen icon
AmerisourceBergen
November 2020
coronavirus_stock

Manufacturers

Is a contact-free clinical trial possible?

Portrait of Mike Sweeney
Mike Sweeney; Kim McLeod, MPH
World Courier
September 2020
insights CTA DtP image

Patient support launch guide: novel therapies 

Inverted color AmerisourceBergen icon
Lash Group
September 2020
Man working on a laptop computer

Manufacturers

Is your PIE incomplete?

Inverted color AmerisourceBergen icon
Xcenda
September 2020
PIE

Case study: Gaining payer attention through digital innovation

Inverted color AmerisourceBergen icon
Xcenda
September 2020
businessman with laptop reviewing a dashboard

Manufacturers

Rethink field services: Three myths keeping access barriers in front of your product

Inverted color AmerisourceBergen icon
Xcenda
August 2020
female_doctor_virtual_visit

Manufacturers

Solving access, reimbursement, and PAP awareness problems

Inverted color AmerisourceBergen icon
Xcenda
August 2020
Male doctor speaking to patient on a tablet

Manufacturers

Pharma in the field: Sales reps vs. reimbursement and access specialists

Inverted color AmerisourceBergen icon
Xcenda
July 2020
Medical staff wearing masks talking at laptop

Manufacturers

The Future of Payer Engagement: How Pharma Can Break Through

Sarnes_Matt
Matt Sarnes, PharmD; Allen Lising
Biopharma Services
June 2020
tech_blue_laptop

Manufacturers

The Value of Virtual: How Remote Workshops Can Keep Market Access Efforts Moving

AmerisourceBergen icon
Bre Penzner; Nancy Young
Xcenda
May 2020
megaphone

Manufacturers

Distant But Engaged: Transitioning to Virtual Training

Inverted color AmerisourceBergen icon
Xcenda
May 2020
lightbulb shatter

Manufacturers

Mind the (Evidence) Gap

Kim McLeod
Kim McLeod, MPH
Xcenda
February 2020
MindtheGap

Manufacturers

InnomarLive 2019: Commercializing in Canada

Inverted color AmerisourceBergen icon
Innomar Strategies
December 2019

Manufacturers

Biosimilars: Market Insights and Growth Factors

SeanMcGowan
Sean McGowan; Rick Lozano
AmerisourceBergen
September 2019

The growth of biosimilars presents a significant opportunity to reduce the cost of care and provide patients with greater access to affordable treatments. Our experts assess the current state and future of the biosimilars market.

Manufacturers

Biosimilars: Launch Insights From the Field

Inverted color AmerisourceBergen icon
Xcenda
September 2019

How are biosimilar manufacturers approaching patients, providers and payers? What can they do to differentiate? Xcenda shares insight from our field programs.

Manufacturers

How Digital Innovation Drives Improved Market Access Strategies

Inverted color AmerisourceBergen icon
Xcenda
July 2019

In this digital age, how can pharmaceutical manufacturers leverage innovative tools to prove their product's value proposition and overcome market access challenges?

Health Systems

Coordinated Care: The Value of Patient and Provider Satisfaction within Health System Specialty Pharmacies

Inverted color AmerisourceBergen icon
AmerisourceBergen
April 2019

Download this new white paper from IHOC - Coordinated Care: The Value of Patient and Provider Satisfaction within Health System Specialty Pharmacies - to learn the key insights about the role HSSPs play in improving the patient experience and why patient and provider satisfaction are important data points for both payers and manufacturers to consider when deciding to include HSSPs in their networks.

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Stojanovska_Ana
Ana Stojanovska
Biopharma Services
June 2018

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part Two

Stojanovska_Ana
Ana Stojanovska
Biopharma Services
June 2018

An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.

Infographic: The Road to Commercialization in Canada

Inverted color AmerisourceBergen icon
AmerisourceBergen
May 2018

Manufacturers

What Do Payers Think About Digital Health Technologies

Inverted color AmerisourceBergen icon
AmerisourceBergen
September 2017

How are payers thinking about apps, wearables and other digital health technologies?

Manufacturers

The Route to Market Access in Canada

Inverted color AmerisourceBergen icon
Innomar Strategies
September 2017

Understanding the unique considerations for reimbursement in the Canadian pharmaceutical market.